One Wales Medicines interim decisions

Nivolumab for oesophageal and gastric cancer (OW28): Issue date: 11/07/2024

Rituximab for myasthenia gravis (OW12): Last review date: July 2024

Ustekinumab (Stelara®) for the treatment of inflammatory bowel disease in children (OW25): Last review date: May 2024

Vedolizumab (Entyvio®) for the treatment of inflammatory bowel disease in children (OW24): Last review date: May 2024

Infliximab for the treatment of refractory pulmonary sarcoidosis (OW23): Last review date: May 2024

Dabrafenib and trametinib for anaplastic thyroid cancer (OW27): Issue date: April 2024

Abiraterone for non-metastatic and locally advanced, high-risk, hormone-sensitive prostate cancer (OW20): Last review date: April 2024

Bevacizumab for ovarian cancer (OW01): Last review date: February 2024

Bendamustine and rituximab for mantle cell lymphoma (OW09): Last review date: February 2024

Bendamustine and rituximab for indolent lymphomas (OW08): Last review date: February 2024

Rituximab for interstitial lung disease (OW13): Last review date: February 2024

Vonicog alfa (Veyvondi®) for on-demand treatment of bleeding episodes in children with von Willebrand Disease (OW19): Last review date: November 2023

Adalimumab for paediatric intermediate, posterior and pan-uveitis (OW04): Last review date: November 2023

Arsenic trioxide for high risk acute promyelocytic leukaemia (OW06): Last review date: September 2023

Azacitidine for progressive angioimmunoblastic T-cell lymphoma (OW16): Last review date: September 2023

Mepolizumab (Nucala®) for chronic eosinophilic pneumonia (OW15): Last review date: August 2023

Dostarlimab (Jemperli®) for locally advanced rectal cancer (OW26): Issue date: 03/08/2023

Rituximab for pemphigus and pemphigoid (OW10): Last review date: July 2023

Sorafenib for acute myeloid leukaemia (AML) maintenance (OW18): Last review date: June 2023

Vedolizumab (Entyvio®) for the treatment of ICI induced enterocolitis (OW22): Issue date: 02/02/2023

1
2

Follow AWTTC: